Abstract
Diabetic macular edema (DME) is the leading cause of vision loss in people with diabetes and preserve the vision of more than one million Portuguese is a major challenge. Lower real-world injection frequencies of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapies than those of major clinical trials and Guidelines have been reported. This study aimed to assess anti-VEGF treatment patterns in DME patients at a national and regional level.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
